Obinutuzumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), HAS (France) and NICE (England), among others, recommended or restricted obinutuzumab, while CIPM (Spain) did not recommend it.
On the same population the two systems disagree outright: NICE (England) recorded recommended in TA513, while PBAC (Australia) recorded not recommended for “Follicular lymphoma (FL)”.
The file has been open for more than a decade: 12.1 years separate the first record, 25 Jun 2014 at AWMSG (Wales), from the most recent, 2026 at PBAC (Australia).
DMC (Denmark) changed its position: not recommended on 7 Feb 2018, recommended by 24 Jun 2026, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The programme is broad: 15 distinct indication wordings are recorded for obinutuzumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
7 of these 37 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess obinutuzumab, on 25 Jun 2014; CIPM (Spain) did not open a file until 28 Apr 2026 — an unusually long tail of 11.8 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 10 years in total.
9 of the 12 agencies here assessed obinutuzumab more than once, PBAC (Australia) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
obinutuzumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for obinutuzumab reads 18 recommended, 5 not recommended, 4 deferred to NICE and 4 no benefit, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 24 Jun 2026 | Gazyvaro er, i kombination med mycophenolatmofetil (MMF), indiceret til behandling af voksne patienter med aktiv lupus n… | Anbefalet | source |
| HAS (France) | 20 May 2026 | Indication extension | SMR low | source |
| CIPM (Spain) | 28 Apr 2026 | Indicaciones terapéuticas autorizadas: Gazyvaro en combinación con quimioterapia seguido de Gazyvaro en terapia de mante… | not financed by the SNS · art. 92 d | source |
| NICE (England) | 12 Feb 2026 | NICE TA1131 | published appraisal | source |
| AWMSG (Wales) | 22 Jan 2026 | in combination with mycophenolate mofetil (MMF) is indicated for the treatment of adult patients with active Class III o… | excluded, NICE appraised | source |
32 further decisions for obinutuzumab, across 11 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 23 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 37 decisions for obinutuzumab from 12 agencies, 2014 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.